Soon after China has gained the
production capacity of Molybdenum-100 isotope in kilograms, scientists from CAS is able to produce the Mo-99m isotope in high purity by using electron linear accelerator (linac) to shoot a target rich of Mo-100. So far China has to import 100% of its need of the Mo-99 isotope for clinical uses. Most of the clinical Mo-99 isotopes in the world have been created as a byproduct of U-235 fission reactions in nuclear reactors.
This experiment by CAS will help China overcome the shortage on the Mo isotopes when more and more commercial nuclear reactors around the global are being taken out of service. Making the Mo isotopes with linac also has less byproducts to remove in the end.
Paper:
Optimization of target system for the production of 99Mo via 100Mo(γ,n)99Mo reaction
Abstract
With an increase of stopping operation of nuclear reactors worldwide, the supply of medical 99Mo becomes difficult and thus many efforts have been made to find an alternative. A process based on an electron
(linac) system and a100Mo target via the 100Mo (γ,n)99Mo reaction receives a lot of attention due to the relatively low level of co-produced impurities. This process has been recently developed at the Institute of Modern
(IMP) and the Monte Carlo simulation was used to optimize the target system before operating pilot irradiation experiments. First, tungsten and tantalum, as mostly used converter materials, were tested. The yield of 99Mo was evaluated with respect to the converter thickness and the
energy by means of Geant4 simulations. Besides, the specific activity of 99Mo produced from one-stage approach (100Mo target without a converter) and two-stage approach (100Mo target with a converter) was compared when varying the testing conditions. The two-stage approach was selected for the experiment due to the higher specific activity of produced 99Mo at all tested conditions. A target consisting of a 10 mm thickness of the 100Mo tablets and a 2.4 mm thick Ta converter was irradiated for 40 h (50 MeV with 0.2 μA). The Geant4-calculated specific activity of generated 99Mo at the end of bombardment agreed well with the experimental value, which proved high level of accuracy of the Geant4 simulation. In future studies, the Geant4 simulation will be used to optimize the production process when using high power linac system.
News story:
近期,中国科学院近代物理研究所科研团队实现了利用电子加速器制备医用同位素钼-99。相关成果发表在国际同位素领域期刊《应用辐射与同位素》(Applied Radiation and Isotopes)上。
锝-99m(半衰期为6小时)在医疗诊断中被广泛使用,使用量占所有临床诊断放射性同位素使用量的80%以上,其来源主要依靠母体钼-99(半衰期为66小时)发生β-衰变。目前,我国医用钼-99全部依赖进口,而全球大部分的医用钼-99通过核反应堆途径,即铀-235裂变反应产生,但是随着越来越多的核反应堆停止运行,钼-99的供给也变得越发紧张。
为了保障全球医用同位素钼-99的稳定供应,国内外众多科研团队把目光投向利用加速器来制备钼-99。利用加速器辐照富集的稳定同位素钼-100,再通过光中子反应制备钼-99,这种方法具有副产物少、化学分离纯化简便等优势。
中国科学院近代物理研究所核化学研究室与电子加速器中心的科研人员于近日成功开展了制备钼-99的实验。团队利用蒙特卡罗方法,实现了靶系统的优化。他们先利用电子加速器产生的50兆电子伏电子束辐照钽转换靶,产生轫致辐射,再由轫致辐射与钼-100靶片发生光中子反应产生钼-99。
随后,研究团队使用了高纯锗探测器和伽马能谱仪测定了钼-99的产额以及放射性核纯度。实验表明,在使用该方法制备钼-99的过程中,产生的杂质核素水平较低,钼-99产品的放射性纯度可达99.99%。